The Swedish Medical Products Agency is seeking a new mandate to address drug shortages. It wants to take charge of redistributing critical medicines to pharmacies and setting up a stock-based situational awareness system.
Hospitals in Hungary are sounding alarm as rising debts restrict operations, with officials reporting there are very few medical interventions for which the available funding provides sufficient financial coverage.
The Polish government has reallocated €139.5 million from the National Recovery Plan to support the zero-emission economy. The move upset the Polish pharmaceutical sector as the funds were originally intended for drug production.
Belgium's political landscape is undergoing a reshuffle, raising critical questions about how the new Belgian government will address the fragmented state of healthcare. Re-federalisation of the healthcare system is an idea gaining traction.
Czechia has enforced new legislation since 1 June aimed at reducing the impact of drug shortages on patients while enhancing the efficiency of the pharmaceutical market.
Whooping cough incidence in Sweden is on the rise. The Swedish chief epidemiologist advises parents to keep their babies away from people with cold symptoms - similar trends are now seen in other parts of Europe.
The future of Belgium’s pharmaceutical industry is under scrutiny as competition challenges Belgian success. Leading Belgian politicians discussed revamping pharma's road map in a recent conversation with Euractiv.
As Slovak voters go to the polls candidates are fighting for Slovakia's 15 MEP seats with substantially different visions of how EU health legislation should be directed - the EU Pharma Package is central to current concerns.
Bulgarian hospitals have warned the government that it risks mass bankruptcies in the health sector if mandatory salary increases are imposed for health staff.
Poland's pharma employers are using the EU elections to push Polish candidates to commit to implementing the European Vaccination Strategy for 2024-2029.
In its last stretch, the Belgian Presidency of the Council of the EU is discussing regulatory data protection (RDP) for medicinal products. The goal is to balance pharmaceutical innovation with timely patient access across the EU.
As Slovakia edges towards the European elections, candidates are split on the EU's role in health but agree on the importance of the EU’s increased strategic autonomy.
Belgium and the Netherlands are pushing for a need-driven research model prioritising society's requirements, with an emphasis on addressing unmet medical needs, Belgium is viewed as setting the stage for future presidencies.
Bulgaria’s updated position paper on the revision of the EU's pharmaceutical legislation underlines the importance of national competence and focuses on access to new medicines for citizens of poorer countries.
Hungarian President Tamás Sulyok is considering legalising euthanasia in Hungary by granting pardons to people assisting in the death of incurable patients.
The Czech Health Ministry has circulated a draft law to urgently reform the salaries of healthcare workers and doctors, in a move to address long-standing remuneration issues and doctors' protests.
Poland's vaccination finance decision-making process is being scrutinised by a specialised team of experts, comparing their methodology to European standards and identifying areas for improvement.
The pipeline of new antibiotics to curb the antimicrobial resistance crisis remains inadequate. Belgium is developing a new antibiotic class, but success depends on securing vital support and incentives.
Antimicrobial resistance is on the rise, prompting the Swedish government to invite the European Centre for Disease Prevention and Control and the European Commission to review Sweden’s AMR strategy.
The Dutch innovative medicines association, VIG, says amendments to the pharmaceutical legislation adopted by the European Parliament aren't enough to ease concerns.
Polish medical innovation has seen improvements, yet significant challenges remain, according to the latest Access GAP data, with access to innovative therapies and diagnostics increasing.
In Czechia, new data shows over 16,000 patients have been included in the research efforts for new drugs and vaccines, with clinical trials most frequently focusing on oncology and immunology.
Swedish doctors fear Swedish patients may have to pay out-of-pocket for a treatment that targets a genetic cause of the neurodegenerative disease ALS. European authorities will decide this spring whether the drug can be marketed in Europe.
The Bulgarian pharmaceutical industry fears that the country's political crisis could negatively impact the protection of national interests during the negotiations on the new European pharmaceutical legislation.
